key: cord-0839241-sctlf04v
authors: Jemioło, P.; Storman, D.; Orzechowski, P.
title: A Call For Better Methodological Quality Of Reviews On Using Artificial Intelligence For COVID-19 Detection In Medical Imaging - An Umbrella Systematic Review
date: 2021-05-05
journal: nan
DOI: 10.1101/2021.05.03.21256565
sha: d2ec7d8dffb122909bc72bbe82e25ceb4eddebb7
doc_id: 839241
cord_uid: sctlf04v

Objective: In this umbrella systematic review, we screen existing reviews on using artificial intelligence(AI) techniques to diagnose COVID-19 in patients of any age and sex (both hospitalised and ambulatory) using medical images and assess their methodological quality. Methods: We searched seven databases (MEDLINE, EMBASE, Web of Science, Scopus, dblp, CochraneLibrary, IEEE Xplore) and two preprint services (arXiv, OSF Preprints) up to September 1, 2020. Eligible studies were identified as reviews or surveys where any metric of classification of detection of COVID-19 using AI was provided. Two independent reviewers did all steps of identification of records (titles and abstracts screening, full texts assessment, essential data extraction, and quality assessment). Any discrepancies were resolved by discussion. We qualitatively analyse methodological credibility ofthe reviews using AMSTAR 2 and evaluate reporting using PRISMA-DTA tools, leaving quantitative analysis for further publications. Results: We included 22 reviews out of 725 records covering 165 primary studies. This review covers 416,254 participants in total, including 50,022 diagnosed with COVID-19. The methodological quality of all eligible studies was rated as critically low. 91% of papers had significant flaws in reporting quality. More than half of the reviews did not comment on the results of previously published reviews at all. Almost three fourth of the studies included less than 10% of available studies. Discussion: In this umbrella review, we focus on the descriptive summary of included papers. Much wasting time and resources could be avoided if referring to previous reviews and following methodological guidelines. Due to the low credibility of evidence and flawed reporting, any recommendation about automated COVID-19 clinical diagnosis from medical images using AI at this point cannot be provided. Funding: PO was supported by NIH grant AI116794 (the funding body had no role in the design, in any stage of the review, or in writing the manuscript); PJ and DS did not receive any funding. Registration:The protocol of this review was registered on the OSF platform at osf.io/kxrmh

In early December 2019, a new coronavirus epidemic was identified in Wuhan, Hubei Province, China [2] . Coronavirus disease 2019 (COVID-19) is a viral infection spread by direct contact with people with the illness (from droplets generated by sneezing and coughing), or indirectly [3] . It is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As of May 3, 2021, over 152 million people have been diagnosed with COVID-19, with nearly 3.2 million associated deaths 1 . Two first waves of COVID-19 affected many societies, as well as scientific organisations [4] [5] [6] [7] . On January 30, 2020, the World Health Organisation (WHO) issued a public health emergency of international concern (PHEIC) associated with COVID-19, and declared the state of a pandemic on March 11, 2020 [8] .

Disease manifestation is variable, with some infected people remaining asymptomatic (even up to 10% [9] ) and others suffering from mild (including fever, cough and aches) to severe (involving lethargy with dyspnea and increased respiratory rate) and critical manifestations (requiring mechanical ventilation). It may lead to serious neurological, musculoskeletal, or cerebrovascular disorders or may even progress to a life-threatening respiratory syndrome in some patients [10, 11] . Moreover, in 80% of patients, COVID-19 leaves one or more long-lasting symptoms, with fatigue, headaches, attentional difficulties, anosmia, memory loss manifested the most frequently [12] . Wide-ranging longer-term morbidity has also been described in the absence of a severe initial illness [13] .

With limited access to healthcare and qualified personnel due to pandemic, an early diagnosis of COVID-19 is essential in preventing transmission of the virus. Identification of infected allows for better management of the pandemic (e.g. isolation, quarantine, hospital admission or admission to the intensive care unit) [14] . the MEDLINE strategy for other sources searched. In Appendix A, we present used strategies. No date or language restrictions were adopted. Additionally, we searched references of included studies for references.

We defined the terms used in our eligibility criteria below. Review refers to a paper identified by authors as a review or a survey. AI refers to computer programs that can perform tasks as intelligent beings [36] . COVID-19 refers to a disease caused by the SARS-CoV-2 virus [37] . Imaging refers to individuals medical imaging results (e.g., CT scans, X-rays, ultrasound images) [38, 39] . Diagnosis refers to the identification of an illness (here: 4 . Performance metrics refers to evaluating machine learning algorithms. These measures are utilised to juxtapose observed data (actual labels) with the predictions of the model [40] .

Using Endnote (Claritive Analytics ® ) and Rayyan [41] , we checked identified references for duplicates. PJ, DS, PO independently screened the remaining references using the latter application. Subsequently, the reviewers (PJ, DS, PO) assessed the full texts for meeting the inclusion criteria separately. We pre-specified an extraction form, and PJ and DS collected all necessary data independently. As specified in the protocol [1] , we gathered information about authors, funding, population, models, outcomes -AI methods performance, and additional analyses, e.g. interpretability.

To improve the understanding of the criteria among the reviewers, we carried out pilot exercises before each phase of this umbrella review (screening of titles and abstracts, full texts assessment, data extraction, credibility assessment). We achieved consensus via discussion if any conflicts (at each step of identification) occurred.

The evaluation was conducted independently by PJ and DS. All discrepancies were resolved by discussion.

We assessed the methodological credibility using an extended version of the QASR tool [42] and AMSTAR 2 [43] with critical items (2, 4, 7, 9, 11, 13, and 15) . In this study, we present only results from the latter instrument since the comprehensive assessment of included reviews will be published separately. The general quality across the study was assessed as critically low when at least one item in a critical domain was evaluated as a flaw.

Additionally, we assessed the quality of reporting in included studies using the PRISMA-DTA Checklist [44] . We rated each module on the 3-item scale: 0 (no with no compliance), 0.5 (partial yes with fragmentary compliance), 1 (yes with total compliance). Next, the results were summed, and the overall score was then assigned. Applying the Li et al. method [45] , we differentiated the quality of reporting as follows:

• major flaws when the final score was ≤ 15.0,

• minor flaws when the final score was between 15.5 and 21.0,

• minimal flaws when the final score was ≥ 21.5.

In this umbrella review, we focus on the descriptive summary of included papers regarding quality and reporting on population, models, and interpretability. To identify a scale of wasting of time and resources, we also extracted bibliometric data about publishing dates (availability), sending to the editors (first and last version), and acceptance. Moreover, we checked how much evidence overlap across included reviews. In all tables and figures, included reviews are sorted by date of the last received version of the article; if it was not available, we used acceptance or published date (available online), whichever first occurred.

The quantitative analysis and following additional analyses will be published separately, as well as extended credibility evaluation. Thus, we do not present a subgroup analysis and investigation of heterogeneity or sensitivity analysis in this paper.

After removing duplicates, we screened 725 studies, of which 33 were read in the form of full texts. In total, we included 22 reviews for qualitative synthesis. Our reporting is consistent with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [68] . The full study flow is presented in Figure 1 .

The bibliometric characteristics of included studies are shown in Table 1 and in Appendix D. The lists of included and excluded studies (with reasons) are presented in Appendices B and C, respectively. None of the studies included meta-analysis, but one summarised the results as an average without weights [60] .

There were 399,374 participants in total in analysed studies. 46,753 of them suffered from COVID-19 (12%). None of the reviews provided information about ethnicity, smoking, and comorbidities (diabetes mellitus, cardiovascular disorders, obesity, respiratory diseases, autoimmunological, or others). Only one review [57] reported on age and gender proportion. Table 2 presents detailed features. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

The general quality of all included studies is critically low (see Figure 2 ). 6 [51] [52] [53] 55, 57, 66] reviews provided full information about sources of funding and conflict of interest. It was the most satisfied item. None of the studies provided a list of excluded papers, explanation of eligible study design and sources of funding in included studies. A heatmap with all authors' judgements regarding AMMSTAR 2 items per specific review can be found in Appendix H. In Appendix I, we also included summarised results per specific review.

Due to the lack of quantitative synthesis in the included reviews, we decided to lower the cut-offs for the overall reporting quality assessment. The thresholds were changed as follows: ≤ 14.5, 14.5-21.0, and ≥ 21.0 for major, minor or minimal flaws, respectively.

Major flaws are present among 20 of included papers. All the rest [57, 66] reviews contain minor drawbacks (see Figure 3 and Appendices F and G). The most affected domains were these concerning additional analyses both in terms of methods and results (all reviews). Similarly, a summary of evidence was not reported in any review. 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2021. ;  Furthermore, 12 of included papers ( [46, 48, [51] [52] [53] 55, [57] [58] [59] [60] 66, 67] ) reported fully on funding. Additionally, 11 reviews ( [46, 47, 49, 54, 55, 58, 59, 61, 62, 65, 66] ) and 8 reviews ( [46, 48, 49, 54-56, 60, 66] ) described rationale and objectives in the introduction adequately. These were the most satisfied domains.

The mean overall score of reporting quality across the included reviews equals 6.23 (1.5-17.5 ). Across all items and studies, the most frequent score was 0 (no) with 67%. 19% of the times, we assessed the items as 0.5 (partially yes).

A heatmap with all authors' judgements regarding PRISMA-DTA items per specific review can be found in Appendix F. In Appendix G, we also included summarised results per specific review.

The included studies were published or available online without peer-reviewing from April 11, 2020 to October 12 2020 (see Appendix B). In Figure 4 , we presented a cumulative (from April to September 2020) chart of all 165 primary studies included in discussed reviews. The number of included interesting studies (related to our research question) in selected reviews ranged from 1 [51] [52] [53] to 106 [62] . Additionally, we present the percentage of unique articles per review. Unique means that such a study was introduced by a particular review.

50% of all primary studies (the half-saturation constant) were included at least once before the end of July. However, the same number of papers was available for inclusion three months earlier. Figure 4 : The cumulative chart of included, available, and unique primary papers among included reviews.

Investigating the citations between the reviews, we considered two different scenarios: citing only published reviews and citing both published and preprint versions. In the first case, 0.81 (0-4) reviews were cross-cited. While in the second condition, 1.1 (0-7) published papers or preprints were quoted by the authors of the subsequent reviews. Notably, 12 (55%) of reviews did not cite any previous reviews at all.

In the next step, we analysed how extensive was the search performed by the authors of the reviews, i.e. to which extent the authors identified the primary studies available up to reference date. By a reference date, we considered the day that the review was either received, or accepted by the editors, or published (See Appendix B). The mean percentage of the primary studies covered was 14%, . Relaxing this condition to the date the last cited paper included in the review was available, the mean percentage of covered studies increased to 24% . For the full details, see Table 10 (Appendix E).

14% of studies did not include any new paper into consideration. The mean unique primary studies included in particular review was 7.24 (0-45).

Since the emergence of COVID-19 pandemic, over 120,000 related papers (and growing) were published, according to the LitCovid tracking website [69] and NIH OPA iSearch COVID-19 Portfolio 5 . The urgency of reporting novel findings and high pressure to publish COVID-19 related research quickly has been reported to lead to exceptions to high standards of quality [70, 71] , lowering methodological credibility of some of the articles [72] , or even accepting papers with many analytical errors [73] . Even the quality of the papers published in the three of the most prestigious journals in the field of healthcare: the New England Journal of Medicine, The Lancet, and the Journal of the American Medical Association, was reported to be below their average [74] . Lowered methodological credibility of COVID-19 research papers was also observed in 686 COVID-19 screened articles extracted by Jung et al. from 14,787 COVID-19 papers [75] . An analysis of reviews on COVID-19 by Yu et al. [76] also showed their unsatisfactory credibility. Out of 17 available reviews published before September 1, 2020, 5 (29%) were found to be of low and the remaining 12 (71%) of critically low quality. This is also in line with Li et al. [31] who assessed 63 systematic reviews (25%) to have low and 150 (62%) to have critically low quality. The authors also evaluated reporting using PRISMA [77] , and the median score was 14 (10) (11) (12) (13) (14) (15) (16) (17) (18) . This adds on top of generally low quality of reporting of DL performance from medical images, with high risk of bias present in 58 out of 81 of the existing studies (72%) [78] .

Similar conclusions come from our study -we report that the quality of the included reviews was critically low. There were several critical domains that all the reviews failed to meet (selection criteria, list of excluded 5 See: https://icite.od.nih.gov/covid19/search/. Accessed on May 3, 2021.

6 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. studies, discussing heterogeneity). Poor quality is not related only to COVID-19 articles and AI. Still, it occurs in many fields like bariatric surgery with 99% critically low articles [79] , psychology with 95% [80] or methodological where 53 out of 63 publications were critically low of quality [81] . What is more, the reporting was also poor. Three PRISMA-DTA domains were fully flawed in all reviews (additional analyses in methods and results descriptions, summary of evidence and discussion). Only in one review [64] , the authors provided description of methods used for synthesis partially. Although the included studies focused on diagnostics, the authors hardly report any accuracy measure and explicit description of the extraction process.

In the reviewed works, we found multiple disagreements on the numbers extracted from the primary studies. We found no data on many population features because of missing information and misleading or unclear statements, e.g. providing different information in text and figures and tables. Lack of scientific precision, e.g. reporting the number of cases, understood either as X-Ray images, or patients, without any discussion if the cases were symptomatic or not. Inconsistencies were also noticed in reporting of DL architecture. For instance, the following names were used across multiple studies: ResNet-18, ResNet18, resnet-18, 18-layer ResNet. In some of the papers, the architecture was not reported at all. Some level of discrepancy was also observed in extracting the measurements of AI models performance. For example, the diagnostic effectiveness metrics from primary studies were either not reported or incorrectly reported by multiple studies. Such negligence may lead to further replicating the errors by subsequent studies and should be corrected before releasing the paper, or soon after in an updated version or erratum.

The amount of waste and poor biomedical research quality is staggering [70, 82] . Papers that do not bring any additional knowledge to the field can be deemed redundant in line with multiple papers and International Committee of Medical Journal Editors (ICMJE) guidelines [83] [84] [85] [86] .

Many of the reviews included in this paper did not contribute to strengthening the evidence on using AI in diagnosing COVID-19 from medical imaging. Those works have not even identified and correctly cited preexisting studies, which is deemed the essence of any research. Some of the potential explanations are that multiple similar studies might have been initiated around the same time and prolonged review times impacted their content. Alternatively, the papers were too broadly focused and have not actually touched on application of AI to medical imaging. As the research questions might have not been strict, the reviews might have been focused on vast areas, e.g. using AI in the battle of COVID-19.

The low credibility of evidence, flawed reporting (e.g. on population characteristics), could be associated with lack of knowledge of reporting standards, clinical practice, or misunderstandings regarding AI techniques.

Proper reporting of deep learning performance from primary research studies is challenging. Naude [32] has pointed out some of the major concerns regarding adoption of AI in COVID-19 research, including data availability, sufficient quality of the data (lack of noise and outliers) as well as privacy protection. Still many studies do not share the source code as open source, which highly limits reproducibility of their findings [87, 88] .

Our umbrella review has the following strengths. First, the search strategy was comprehensive based on adequate inclusion criteria related to research question, and spanned across a wide selection of existing data sources: papers and preprints. This selection was further expanded by searching the references of included papers to identify new works. Noteworthy, the searches were not limited in terms of format or language. The process of our review was rigorous as the study was proceeded by the publication of protocol. We used the most up-to-date and applicable tools to assess credibility and quality of reporting -AMSTAR 2 and PRISMA with extension for DTA, respectively. Nevertheless, these instruments have been designed for reviews in the fields of medicine and health sciences, where the formulation of the research question is structured, the methodology is validated and the quantitative synthesis of results is more popular. There are also other limitations associated with this study. Although our exhaustive and sensitive search covered multiple aspects, some studies might have still been missed. We did not search for Chinese data sources that could include many valuable papers. Secondly, it must be noted that the vast majority of the included studies focused on a broader context than purely diagnosing COVID-19 from medical images.

In this study, we have investigated wasting among the reviews. We based on the date of publishing of the last included primary study in particular review. This approach aims at assessing the depth of the search performed by the authors. We assumed that if the authors included a given study, they should have had the required knowledge about all the studies that appeared prior that date. This approach relaxes the strict requirement to include all the studies that appeared before the review was published and seems to more objectively measure the quality of the search. Due to the lack of validated method, we based this approach on intuition.

This study does not include quantitative analysis and extended credibility evaluation, as this is planned to be addressed in the follow-up papers. Thus, we also do not present a subgroup analysis and investigation of heterogeneity nor sensitivity analysis.

The COVID-19 research is quickly moving forward, each day hundreds of new papers are published. As AI starts to play increasingly important role in clinical practice [89, 90] , it is crucial to properly evaluate its performance using well established standards.

In this paper, we synthesised and assessed the quality of the 22 reviews that mention using AI on COVID-19 medical images. We reviewed them and critically assessed their quality using well established instruments from PRISMA-DTA [44] and AMSTAR 2 [43] .

7 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021.

The overall conclusion from this study is that we still need high quality evidence to prove the effectiveness of AI in detecting COVID-19 from medical images. The recommendation on using AI to detect COVID-19 in medical images can not be provided until more credible studies are presented, and the certainty of evidence becomes evaluated using well established techniques.

In order to accomplish this, we urge the authors of the systematic reviews to use PRISMA and AMSTAR 2, and the authors of primary studies to adapt the Checklist for Artificial Intelligence in Medical Imaging (CLAIM) -a new standard for transparency and reproducibility of the research [91] .

It is high time to adapt best practices and improve the quality of the research, as well as to apply higher scrutiny in filtering out nonconstructive contributions.

We followed CRediT (Contributor Roles Taxonomy) to report on authors contributions. 

Authors declare that they have no conflict of interest.

PO was supported by NIH grant AI116794 (the funding body had no role in the design, in any stage of the review, or in writing the manuscript); PJ and DS did not receive any funding.

Full extraction forms and code used in this research can be accessed via contact with corresponding author.

8 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ; 3. 'recogni*':ti,ab OR 'classif*':ti,ab OR 'regress*':ti,ab OR 'clusteri*':ti,ab OR 'discriminat A.3 Web of Science . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.05.03.21256565 doi: medRxiv preprint

((TITLE-ABS-KEY ("Coronavirus Infection*" OR "Coronavirus" OR "Betacoronavirus") OR TITLE-ABS-KEY (("corona*" OR "corono*") W/1 ("virus*" OR "viral*" OR "virinae*")) OR TITLE-ABS-KEY ("coronavirus*" OR "Severe acute respiratory syndrome related coronavirus" OR "Severe acute respiratory syndrome coronavirus 2" OR "coronovirus*" OR "coron?virinae*" OR "2019-nCoV" OR "2019nCoV" OR "2019-CoV" OR "nCoV2019" OR "nCoV-2019" OR "COVID-19" OR "COVID19" OR "CORVID-19" OR "CORVID19" OR "WN-CoV" OR "WNCoV" OR "HCoV-19" OR "HCoV19" OR "CoV" OR "2019 novel*" OR "2019 novel coronavirus" OR "2019 nCoV" OR "Ncov" OR "n-cov" OR "SARS-CoV-2" OR "SARSCoV-2" OR "SARSCoV2" OR "SARS-CoV2" OR "SARSCov19" OR "SARS-Cov19" OR "SARSCov-19" OR "SARS-Cov-19" OR "SARSr-cov" OR "Ncovor" OR "Ncorona*" OR "Ncorono*" OR "NcovWuhan*" OR "NcovHubei*" OR "NcovChina*" OR "NcovChinese*" OR "Wuhan virus*" OR "novel CoV" OR "CoV 2" OR "CoV2" OR "betacoron?vir*") OR TITLE-ABS-KEY ((("respiratory*" W/2 ("acute*" OR "symptom*" OR "disease*" OR "illness*" OR "condition*")) OR "sea-food market*" OR "seafood market*" OR "food market*" OR "foodmarket*") W/10 ("Wuhan*" OR "Hubei*" OR "China*" OR "Chinese*" OR "Huanan*")) OR TITLE-ABS-KEY (("outbreak*" OR "wildlife*" OR "wild-life" OR "pandemic*" OR "epidemic*") W/3 ("Wuhan*" OR "Hubei*" OR "China*" OR "Chinese*" OR "Huanan*")) OR TITLE-ABS-KEY ("anti-flu*" OR "anti-influenza*" OR "antiflu*" OR "antinfluenza*")) AND NOT (TITLE-ABS-KEY ("influenza" OR "AIDS" OR "immunodeficiency virus" OR "HIV" OR "sexually transmitted disease" OR "sexually transmitted infections" OR "STD" OR "STI"))) AND ((TITLE-ABS-KEY ("recogni*" OR "classif*" OR "regress*" OR "clusteri*" OR "discriminat*" OR "detect*" OR "categori*" OR "estimat*")) OR (TITLE-ABS-KEY ("Machine Learning" OR "DL" OR "Deep Learning" OR "Representation Learning" OR "Transfer Learning" OR "AI" OR "Artificial intelligen*" OR "Computational Intelligen*")) OR (TITLE-ABS-KEY ("MLP" OR "multi-layer perceptron" OR "multi layer perceptron" OR "LSTM" OR "BLSTM" OR "GAN" OR "generative adversarial" OR "RNN" OR "ANN" OR "DNN" OR "CNN" OR "NN" OR "Neural Network*" OR "SVM" OR "SVC" OR "support vector*" OR "LDA" OR "QDA" OR "discriminant analysis" OR "naive bayes*" OR "knn" OR "nearest neighb*" OR "Decision*" OR "Expert*" OR "Logistic Regress*" OR "Linear Regress*" OR "Random Forest" OR "Gradient Boost*" OR "AdaBoost" OR "XGBoost" OR "LightGBM" OR "classifier*" OR "regressor*"))) AND (TITLE-ABS-KEY ("diagnostic imaging" OR "computer assisted" OR "computer-assisted" OR "Tomography" OR "Emission Computed" OR "Emission-Computed" OR "X-ray computed" OR "X ray computed" OR "X-ray-computed" OR "echography" OR "magnetic resonance imaging" OR "mri" OR "magnetic resonance imaging" OR "microscop*" OR "photograph*" OR "holograph*" OR "radiograph*" OR "spectroscop*" OR "stroboscop*" OR "subtraction technique*" OR "thermograph*" OR "tomograph*" OR "transilluminat*" OR "ultrasonograph*" OR "ultrasound" OR "imaging" OR "scan*" OR "X-Ray" OR "X Ray" OR "CT Scan" OR "Computed Tomography" OR "CT" OR "PET" OR "PET-CT" OR "positron emission tomograph*" OR "MRI" OR "fMRI" OR "NMRI" OR "scintigraph*" OR "Doppler echography" OR "sonograph*" OR "ultraso*" OR "doppler" OR "magnetic resonance imag*")) AND (ALL("overview*" OR "review*" OR "survey*"))

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.05.03.21256565 doi: medRxiv preprint A.6 IEEE Xplore (("Coronavirus Infection" OR "Coronavirus" OR "Betacoronavirus") OR (("corona" OR "corono") NEAR/1 ("virus" OR "viral" OR "virinae")) OR ("Abstract":"coronavirus" OR "Severe acute respiratory syndrome related coronavirus" OR "Severe acute respiratory syndrome coronavirus 2" OR "coronovirus" OR "coron?virinae" OR "2019-nCoV" OR "2019nCoV" OR "2019-CoV" OR "nCoV2019" OR "nCoV-2019" OR "COVID-19" OR "COVID19" OR "CORVID-19" OR "CORVID19" OR "WN-CoV" OR "WNCoV" OR "HCoV-19" OR "HCoV19" OR "CoV" OR "2019 novel" OR "2019 novel coronavirus" OR "2019 nCoV" OR "Ncov" OR "n-cov" OR "SARS-CoV-2" OR "SARSCoV-2" OR "SARSCoV2" OR "SARS-CoV2" OR "SARSCov19" OR "SARS-Cov19" OR "SARSCov-19" OR "SARS-Cov-19" OR "SARSr-cov" OR "Ncovor" OR "Ncorona" OR "Ncorono" OR "NcovWuhan" OR "NcovHubei" OR "NcovChina" OR "NcovChinese" OR "Wuhan virus" OR "novel CoV" OR "CoV 2" OR "CoV2" OR "betacoron?vir") OR ("Document title":"coronavirus" OR "Severe acute respiratory syndrome related coronavirus" OR "Severe acute respiratory syndrome coronavirus 2" OR "coronovirus" OR "coron?virinae" OR "2019-nCoV" OR "2019nCoV" OR "2019-CoV" OR "nCoV2019" OR "nCoV-2019" OR "COVID-19" OR "COVID19" OR "CORVID-19" OR "CORVID19" OR "WN-CoV" OR "WNCoV" OR "HCoV-19" OR "HCoV19" OR "CoV" OR "2019 novel" OR "2019 novel coronavirus" OR "2019 nCoV" OR "Ncov" OR "n-cov" OR "SARS-CoV-2" OR "SARSCoV-2" OR "SARSCoV2" OR "SARS-CoV2" OR "SARSCov19" OR "SARS-Cov19" OR "SARSCov-19" OR "SARS-Cov-19" OR "SARSr-cov" OR "Ncovor" OR "Ncorona" OR "Ncorono" OR "NcovWuhan" OR "NcovHubei" OR "NcovChina" OR "NcovChinese" OR "Wuhan virus" OR "novel CoV" OR "CoV 2" OR "CoV2" OR "betacoron?vir") OR ((("respiratory" NEAR/2 ("acute" OR "symptom" OR "disease" OR "illness" OR "condition")) OR "sea-food market" OR "seafood market" OR "food market" OR "foodmarket") NEAR/10 ("Wuhan" OR "Hubei" OR "China" OR "Chinese" OR "Huanan")) OR (("outbreak" OR "wildlife" OR "wild-life" OR "pandemic" OR "epidemic") NEAR/3 ("Wuhan" OR "Hubei" OR "China" OR "Chinese" OR "Huanan")) OR ("anti-flu" OR "anti-influenza" OR "antiflu" OR "antinfluenza")) AND (("overview*" OR "review*" OR "survey*") OR "Mesh Terms":"review") CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.05.03.21256565 doi: medRxiv preprint A.9 OSF Preprints (("Coronavirus Infection*" OR "Coronavirus" OR "Betacoronavirus" OR"corona*" OR "corono*" OR "coronavirus*" OR "Severe acute respiratory syndrome related coronavirus" OR "Severe acute respiratory syndrome coronavirus 2" OR "coronovirus*" OR "coron?virinae*" OR "2019-nCoV" OR "2019nCoV" OR "2019-CoV" OR "nCoV2019" OR "nCoV-2019" OR "COVID-19" OR "COVID19" OR "CORVID-19" OR "CORVID19" OR "WN-CoV" OR "WNCoV" OR "HCoV-19" OR "HCoV19" OR "CoV" OR "2019 novel*" OR "2019 novel coronavirus" OR "2019 nCoV" OR "Ncov" OR "n-cov" OR "SARS-CoV-2" OR "SARSCoV-2" OR "SARSCoV2" OR "SARS-CoV2" OR "SARSCov19" OR "SARS-Cov19" OR "SARSCov-19" OR "SARS-Cov-19" OR "SARSr-cov" OR "NcovOR " OR "Ncorona*" OR "Ncorono*" OR "NcovWuhan*" OR "NcovHubei*" OR "NcovChina*" OR "NcovChinese*" OR "Wuhan virus*" OR "novel CoV" OR "CoV 2" OR "CoV2" OR "betacoron?vir*" OR "respiratory*" OR "sea-food market*" OR "seafood market*" OR "food market*" OR "foodmarket*" OR "outbreak*" OR "wildlife*" OR "wild-life" OR "pandemic*" OR "epidemic*" OR "anti-flu*" OR "anti-influenza*" OR "antiflu*" OR "antinfluenza*") NOT ("influenza" OR "AIDS" OR "immunodeficiency virus" OR "HIV" OR "sexually transmitted disease" OR "sexually transmitted infections" OR "STD" OR "STI")) AND ("review*" OR "overview*" OR "survey*") AND ("diagnostic imaging" OR "computer assisted" OR "computer-assisted" OR "Tomography" OR "Emission Computed" OR "Emission-Computed" OR "X-ray computed" OR "X ray computed" OR "X-ray-computed" OR "echography" OR "magnetic resonance imaging" OR "mri" OR "magnetic resonance imaging" OR "microscop*" OR "photograph*" OR "holograph*" OR "radiograph*" OR "spectroscop*" OR "stroboscop*" OR "subtraction technique*" OR "thermograph*" OR "tomograph*" OR "transilluminat*" OR "ultrasonograph*" OR "ultrasound" OR "imaging" OR "scan*" OR "X-Ray" OR "X Ray" OR "CT Scan" OR "Computed Tomography" OR "CT" OR "PET" OR "PET-CT" OR "positron emission tomograph*" OR "MRI" OR "fMRI" OR "NMRI" OR "scintigraph*" OR "Doppler echography" OR "sonograph*" OR "ultraso*" OR "doppler" OR "magnetic resonance imag*") AND ("recogni*" OR "classif*" OR "regress*" OR "clusteri*" OR "discriminat*" OR "detect*" OR "categori*" OR "estimat*" OR "Machine Learning" OR "DL" OR "Deep Learning" OR "Representation Learning" OR "Transfer Learning" OR "AI" OR "Artificial intelligen*" OR "Computational Intelligen*" OR "MLP" OR "multi-layer perceptron" OR "multi layer perceptron" OR "LSTM" OR "BLSTM" OR "GAN" OR "generative adversarial" OR "RNN" OR "ANN" OR "DNN" OR "CNN" OR "NN" OR "Neural Network*" OR "SVM" OR "SVC" OR "support vector*" OR "LDA" OR "QDA" OR "discriminant analysis" OR "naive bayes*" OR "knn" OR "nearest neighb*" OR "Decision*" OR "Expert*" OR "Logistic Regress*" OR "Linear Regress*" OR "Random Forest" OR "Gradient Boost*" OR "AdaBoost" OR "XGBoost" OR "LightGBM" OR "classifier*" OR "regressor*") 13 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.05.03.21256565 doi: medRxiv preprint B Included studies C Excluded studies with reasons Table 4 : Exluded studies with reasons.

ID Reason [92] Wrong Study Design [93] Wrong Patient Population [94] Wrong Target Condition [95] Wrong Outcomes [96] Wrong Outcomes [97] Wrong Outcomes [98] Wrong Outcomes [99] Wrong CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ; . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.05.03.21256565 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 5, 2021. ; Table  9 : Full characteristics of included reviews, part 5. Figure 4) ; D -number of unique included primary papers (see Figure 4 ); E -cumulative sum of unique included primary papers; J -cited reviews that were published; K -cited reviews both published and available as preprints; X -all primary papers available to the date of publishing last included study; Y -all primary papers available to the chosen date (see Appendix B, see Figure 4 )). 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 5, 2021. ; https://doi.org/10.1101/2021.05.03.21256565 doi: medRxiv preprint

Severe acute respiratory syndrome related coronavirus" or "Severe acute respiratory syndrome coronavirus 2" or "coronovirus*" or "coron?virinae*" or "2019-nCoV" or "2019nCoV" or "2019-CoV" or "nCoV2019" or "nCoV-2019" or "COVID-19" or "COVID19" or "CORVID-19" or "CORVID19" or "WN-CoV" or "WNCoV" or "HCoV-19" or "HCoV19" or "CoV" or "2019 novel*" or "2019 novel coronavirus" or "2019 nCoV" or "Ncov" or "n-cov" or "SARS-CoV-2" or "SARSCoV-2" or "SARSCoV2" or "SARS-CoV2" or "SARSCov19" or "SARS-Cov19" or "SARSCov-19" or "SARS-Cov-19" or "SARSr-cov" or "Ncovor" or "Ncorona*" or "Ncorono*" or "NcovWuhan*" or "NcovHubei*" or "NcovChina*" or "NcovChinese*" or

NEAR/2 ("acute*" or "symptom*" or "disease*" or "illness*" or "condition*")) or "sea-food market*" or "seafood market*" or "food market*" or "foodmarket*") NEAR/10 ("Wuhan*" or "Hubei*" or "China*" or

outbreak*" or "wildlife*" or "wild-life" or "pandemic*" or "epidemic*") NEAR/3 ("Wuhan*" or "Hubei*" or "China*" or

anti-flu*" or "anti-influenza*" or "antiflu*" or

#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7

MLP" or (("multi-layer" or "multi layer") and "perceptron") or "LSTM" or "BLSTM" or "GAN" or "generative adversarial" or "RNN" or "ANN" or "DNN" or "CNN" or "NN" or "Neural Network*" or "SVM" or "SVC" or "support vector*" or "LDA" or "QDA" or "discriminant analysis" or "naive bayes*" or "knn" or

Emission-Computed" or "X-ray computed" or "X ray computed" or "X-ray-computed" or "echography" or "magnetic resonance imaging" or "mri" or "magnetic resonance imaging" or "microscop*" or "photograph*" or "holograph*" or "radiograph*" or "spectroscop*" or "stroboscop*" or "subtraction technique*" or "thermograph*" or "tomograph*" or "transilluminat*" or "ultrasonograph*" or "ultrasound" or "imaging" or "scan*" or "X-Ray" or "X Ray" or "CT Scan" or "Computed Tomography" or "CT" or "PET" or "PET-CT" or

overview*" or "review*" or "survey*"))

#8 not #9) and (#10 or #11 or #12) and (#19 or #20) and #23

Diagnosing covid-19 from medical images with artificial intelligence -an umbrella survey (registration)

New virus discovered by chinese scientists investigating pneumonia outbreak

World Health Organization, World Health Organization

Impact of the 1st and 2nd wave of the covid-19 pandemic on primary or revision total hip and knee arthroplasty-a cross-sectional single center study

County-level longitudinal clustering of covid-19 mortality to incidence ratio in the united states

First and second covid-19 waves in japan: A comparison of disease severity and characteristics: Comparison of the two covid-19 waves in japan

The effects of the first and second wave of covid-19 pandemic on public health

World Health Organization et al. World health organization coronavirus disease 2019 (covid-19) situation report

Epidemiology for public health Istituto Superiore di Sanità. Covid-19 integrated surveillance: key national data

Clinical characteristics of coronavirus disease 2019 in china

More than 50 long-term effects of covid-19: a systematic review and meta-analysis

Management of post-acute covid-19 in primary care

Lower mortality of covid-19 by early recognition and intervention: experience from jiangsu province

Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (covid-19)

Detection of sars-cov-2 in different types of clinical specimens

Antibody tests for identification of current and past infection with sars-cov-2

A characteristic chest radiographic pattern in the setting of covid-19 pandemic

The role of chest radiography in confirming covid-19 pneumonia

Correlation of chest ct and rt-pcr testing for coronavirus disease 2019 (covid-19) in china: a report of 1014 cases

The accuracy of chest ct in the diagnosis of covid-19: An umbrella review

Opportunities and obstacles for deep learning in biology and medicine

Artificial intelligence in radiology

Deep learning in radiology

Real-time automatic detection system increases colonoscopic polyp and adenoma detection rates: a prospective randomised controlled study

A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis. The lancet digital health

Beyond performance metrics: automatic deep learning retinal oct analysis reproduces clinical trial outcome

Mapping the landscape of artificial intelligence applications against covid-19

Reporting and methodological quality of covid-19 systematic reviews needs to be improved: an evidence mapping

Artificial intelligence vs covid-19: limitations, constraints and pitfalls

Following the science? comparison of methodological and reporting quality of covid-19 and other research from the first wave of the pandemic

Coronaviridae Study Group of the International et al. The species severe acute respiratory syndromerelated coronavirus: classifying 2019-ncov and naming it sars-cov-2

Diagnosing covid-19 from medical images with artificial intelligence -an umbrella survey

Artificial intelligence: Definition, examples, and applications. Encyclopedia Britannica

Review of the 2019 novel coronavirus (sars-cov-2) based on current evidence

Medical Imaging Systems Techniques and Applications: Computational Techniques

Medical Imaging: Artificial Intelligence, Image Recognition, and Machine Learning Techniques

Performance metrics (error measures) in machine learning regression, forecasting and prognostics: Properties and typology

Rayyan-a web and mobile app for systematic reviews

Quality assessment of systematic reviews (qasr)

Amstar 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the prisma-dta statement

Quality of reporting of systematic reviews published in "evidence-based

Review of artificial intelligence techniques in imaging data acquisition, segmentation and diagnosis for covid-19

Detection of covid-19 from chest x-ray images using artificial intelligence: An early review

The role of imaging in the detection and management of covid-19: a review

A review on the use of artificial intelligence for medical imaging of the lungs of patients with coronavirus disease 2019

A review of modern technologies for tackling covid-19 pandemic

Role of chest radiograph (cxr) in covid-19 diagnosis and management

Diagnostic methods and potential portable biosensors for coronavirus disease 2019

Chest ct in covid-19 pneumonia: A review of current knowledge. Diagnostic and Interventional Imaging

Review on machine and deep learning models for the detection and prediction of coronavirus

Deep learning applications in pulmonary medical imaging: recent updates and insights on covid-19. Machine vision and applications

Jamshid Dehmsehki, and Sotirios Bisdas. Current landscape of imaging and the potential role for artificial intelligence in the management of covid-19

Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal

A survey on applications of artificial intelligence in fighting against covid-19

Artificial intelligence (ai) and big data for coronavirus (covid-19) pandemic: A survey on the state-ofthe-arts

A review of automated diagnosis of covid-19 based on scanning images

A review of mathematical modeling, artificial intelligence and datasets used in the study, prediction and management of covid-19

Automated detection and forecasting of covid-19 using deep learning techniques: A review

Artificial intelligence in the battle against coronavirus (covid-19): a survey and future research directions

A survey on the use of ai and ml for fighting the covid-19 pandemic

A review on deep learning techniques for the diagnosis of novel coronavirus (covid-19)

Machine learning for covid-19 detection and prognostication using chest radiographs and ct scans: a systematic methodological review

Covid-19 control by computer vision approaches: A survey

Prisma 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews

Keep up with the latest coronavirus research

Against pandemic research exceptionalism

Covid-19: 146 researchers raise concerns over chloroquine study that halted who trial

Coronavirus disease 2019: the harms of exaggerated information and non-evidencebased measures

Scientific quality of covid-19 and sars cov-2 publications in the highest impact medical journals during the early phase of the pandemic: A case control study

Methodological quality of covid-19 clinical research

Assessment of the quality of systematic reviews on covid-19: A comparative study of previous coronavirus outbreaks

Prisma 2009 flow diagram. The PRISMA statement

Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies

The quality of systematic reviews/meta-analyses published in the field of bariatrics: A cross-sectional systematic survey using amstar 2 and robis

Psychometric measurements of amstar 2 in a sample of meta-analyses indexed in psycinfo

Authors should clearly report how they derived the overall rating when applying amstar 2-a cross-sectional study

Protect us from poor-quality medical research

Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication international committee of medical journal editors updated

Repetitive, duplicate, and redundant publications: a review for authors and readers

Consensus and contention regarding redundant publications in clinical research: cross-sectional survey of editors and authors

Ethical issues in biomedical publication

The importance of open access, open source, and open standards for libraries

Reproducibility of computational workflows is automated using continuous analysis

Rapid triage for covid-19 using routine clinical data for patients attending hospital: development and prospective validation of an artificial intelligence screening test

Artificial intelligence for covid-19: saviour or saboteur? The Lancet

Checklist for artificial intelligence in medical imaging (claim): A guide for authors and reviewers

Early screening of sars-cov-2 by intelligent analysis of x-ray images

Role of biological data mining and machine learning techniques in detecting and diagnosing the novel coronavirus (covid-19): a systematic review

Comparing different deep learning architectures for classification of chest radiographs

A comprehensive review of the covid-19 pandemic and the role of iot, drones, ai, blockchain, and 5g in managing its impact

How big data and artificial intelligence can help better manage the covid-19 pandemic

Imaging of covid-19 pneumonia: Patterns, pathogenesis, and advances

Utility of artificial intelligence amidst the covid 19 pandemic: a review

Zero-shot learning and its applications from autonomous vehicles to covid-19 diagnosis: A review. Intelligence-based medicine

Role of edge device and cloud machine learning in point-of-care solutions using imaging diagnostics for population screening

Systematic review of artificial intelligence techniques in the detection and classification of covid-19 medical images in terms of evaluation and benchmarking: Taxonomy analysis, challenges, future solutions and methodological aspects

A systematic review on recent trends in transmission, diagnosis, prevention and imaging features of covid-19

The authors would like to thank Prof. Jason H. Moore from the University of Pennsylvania for his kind support and useful suggestions.

A.1 MEDLINE